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Abstract
Purpose of Review Treatment with a defibrillator can reduce the risk of sudden death by terminating ventricular arrhythmias. The
identification of patient groups in whom this function reduces overall mortality is challenging. In this review, we summarise the
evidence for who benefits from a defibrillator.
Recent Findings Recent evidence suggests that contemporary pharmacologic and non-defibrillator device therapies are altering
the potential risks and benefits of a defibrillator.
Summary Who benefits from a defibrillator is determined by both the risk of sudden death and the competing risk of other, non-
sudden causes of death. The balance of these risks is changing, which calls into question whether historic evidence for the use of
defibrillators remains robust in the modern era.
Keywords Defibrillator . ICD . Sudden death . Competing risk
Introduction
In 1980, Mirowski et al. reported the first three patients treated
with an automatic implantable defibrillator (AID) [1]. This
early AID was a ‘shock box’, delivering only high-voltage
defibrillation therapy. Later devices evolved to include a pac-
ing function and are now usually described as implantable
cardioverter defibrillators (ICDs). The randomised controlled
trials (RCTs) that followed examined the efficacy of ICD ther-
apy in populations targeted for their high incidence of sudden
cardiac death (SCD). Specifically, these were patients with
prior cardiac arrest, ventricular arrhythmias (VA) or myocar-
dial infarction (MI), or the presence of coronary artery disease
(CAD), left ventricular systolic dysfunction (LVSD), heart
fa i lure or some combinat ion of these problems.
Incrementally, these RCTs established our current understand-
ing of which patients are more, or less, likely to benefit from
an ICD. The importance of several major themes that
progressively emerged from these trials must be recognised
if a thorough examination of this evidence is undertaken.
These include the role of competing risks of death, appropriate
trial design—including length of follow-up and the selection
of a suitable primary endpoint—the technical evolution of the
defibrillator, and incremental advances in prognostic pharma-
cologic and additional device therapy.
Who Benefits From a Secondary Prevention
Defibrillator?
The benefit of an ICD as a secondary prevention treatment
was examined in three major prospective, multi-centre
RCTs. Summary characteristics of these studies are presented
in Table 1. The first published and largest study was the
Antiarrhythmics Versus Implantable Defibrillators (AVID) tri-
al [2•]. Patient eligibility in AVID required one of the follow-
ing: (1) resuscitation from ventricular fibrillation (VF), (2)
syncope with sustained ventricular tachycardia (VT) or (3)
sustained VT with significant associated symptoms and left
ventricular ejection fraction (LVEF) ≤ 40%. AVID enrolled
1016 patients, randomising them to treatment with an ICD
or antiarrhythmic drugs (AADs), primarily amiodarone.
Over a mean follow-up of 18 months, there were 80 and 122
deaths from any cause in the ICD and AAD arms, respectively
This article is part of the Topical Collection on Devices
* John J. V. McMurray
John.McMurray@glasgow.ac.uk
1 British Heart Foundation Cardiovascular Research Centre,
University of Glasgow, Glasgow, Scotland
2 Golden Jubilee National Hospital, Clydebank, Scotland
Current Heart Failure Reports (2018) 15:376–389
https://doi.org/10.1007/s11897-018-0416-6
Ta
bl
e
1
O
ut
lin
e
ch
ar
ac
te
ri
st
ic
s
of
ra
nd
om
is
ed
co
nt
ro
lle
d
tr
ia
ls
ut
ili
si
ng
de
fi
br
ila
to
rs
as
pr
im
ar
y
or
se
co
nd
ar
y
pr
ev
en
tio
n
th
er
ap
y
Se
co
nd
ar
y
pr
ev
en
tio
n
tr
ia
ls
P
ri
m
ar
y
pr
ev
en
tio
n
tr
ia
ls
–i
sc
ha
em
ic
ae
tio
lo
gy
T
ri
al
na
m
e
A
V
ID
[2
•]
C
A
SH
[3
]
C
ID
S
[4
]
M
A
D
IT
[5
]
C
A
B
G
-P
at
ch
[6
]
Y
ea
r
of
pu
bl
ic
at
io
n
19
97
20
00
20
00
19
96
19
97
Y
ea
rs
of
en
ro
llm
en
t
19
93
–1
99
7
19
87
–1
99
6
19
90
–1
99
7
19
90
-
N
R
19
90
-
N
R
In
cl
us
io
n
cr
ite
ri
a
i)
R
es
us
ci
ta
te
d
V
F;
O
R
ii)
su
sV
T
+
sy
nc
op
e;
O
R
iii
)
sy
m
pt
om
at
ic
su
sV
T
+
LV
E
F
≤
40
%
C
A
du
e
to
V
A
i)
do
cu
m
en
te
d
V
F;
O
R
ii)
C
A
re
qu
ir
in
g
de
fi
br
ill
at
io
n
iii
)
su
sV
T
+
sy
nc
op
e;
O
R
iv
)
su
sV
T
+
an
gi
na
or
pr
es
yn
co
pe
if
LV
E
F
≤
35
%
;O
R
v)
un
m
on
ito
re
d
sy
nc
op
e
+
su
bs
eq
ue
nt
sp
on
ta
ne
ou
s
V
T
or
PV
S-
in
du
ce
d
su
sV
T
Pr
ev
io
us
M
I
(>
3
w
ee
ks
)
+
as
ym
pt
om
at
ic
ns
V
T,
E
PS
+
de
sp
ite
pr
oc
ai
na
m
id
e
su
pp
re
ss
io
n
Pl
an
ne
d
C
A
B
G
+
SA
E
po
si
tiv
e
LV
E
F
cu
t-
of
f
N
/A
N
/A
N
/A
≤
35
%
≤
35
%
N
Y
H
A
cr
ite
ri
a
N
/A
N
/A
N
/A
I
to
II
I
I
to
IV
N
o.
ra
nd
om
is
ed
10
16
28
8*
*
65
9
19
6
90
0
N
o.
(%
)
w
ith
N
IC
M
19
3
(1
9.
0)
22
0
63
(9
.6
)
0
0
Fo
llo
w
-u
p,
m
ea
n
(S
D
),
m
on
th
18
.2
(1
2.
2)
57
(3
4)
35
27
32
(1
6)
D
em
og
ra
ph
ic
s
A
ge
,m
ea
n
(S
D
),
ye
ar
65
(1
0.
5)
56
64
(9
.6
)
63
64
(9
)
M
al
e,
%
(N
o.
)
80
(8
08
)
80
(2
30
)
84
.5
(5
57
)
92
(1
72
)
16
(7
59
)
N
Y
H
A
cl
as
s
II
I/
IV
,%
(N
o.
)
9.
5
(9
7)
16
(4
7)
10
.8
(7
1)
N
R
N
R
D
ur
at
io
n
of
C
H
F,
m
ea
n
N
R
N
R
N
R
N
R
n/
a
LV
E
F,
m
ea
n
(S
D
),
%
31
(1
3)
46
(1
8)
34
(1
4)
26
(7
)
27
(6
)
M
ed
ic
at
io
ns
at
ba
se
lin
e,
%
(N
o.
)
A
C
E
in
hi
bi
to
r/
A
R
B
68
.5
(6
80
)
45
(1
25
)
N
R
58
(1
07
)
53
(4
73
)
B
B
29
.4
(2
92
)
33
(9
6)
27
.4
(1
81
)
17
(3
1)
20
(1
83
)
M
R
A
N
R
N
R
N
R
N
R
N
R
C
R
T
0
0
0
0
0
D
es
ig
n
IC
D
vs
an
tia
rr
hy
th
m
ic
IC
D
vs
am
io
.v
s
B
B
IC
D
vs
am
io
.
IC
D
vs
C
M
T
IC
D
vs
C
M
T
Pr
im
ar
y
en
dp
oi
nt
A
C
M
A
C
M
A
C
M
A
C
M
A
C
M
D
ef
ib
ri
lla
to
r
Tr
an
sv
en
ou
s/
ep
ic
ar
di
al
,%
93
/5
44
/5
6
84
/1
0
53
/4
7
0/
10
0
In
te
rn
al
va
lid
ity
Fo
llo
w
-u
p,
%
10
0
10
0
10
0
99
10
0
C
ro
ss
ov
er
s
to
IC
D
,%
(N
o.
)
18
.9
(9
6)
†
5.
8
(1
1)
15
.7
(5
2)
11
(1
1)
4
(1
8)
C
ro
ss
ov
er
s
to
co
nt
ro
l%
(N
o.
)
25
.7
(1
30
)
6.
1
(6
)
28
.1
(9
2)
5
(5
)
12
(5
2)
Curr Heart Fail Rep (2018) 15:376–389 377
T
ab
le
1
(c
on
tin
ue
d)
P
ri
m
ar
y
pr
ev
en
tio
n
tr
ia
ls
–i
sc
ha
em
ic
ae
tio
lo
gy
P
ri
m
ar
y
pr
ev
en
tio
n
tr
ia
ls
–n
on
is
ch
ae
m
ic
or
m
ix
ed
ae
tio
lo
gy
T
ri
al
na
m
e
M
U
S
T
T
[7
]
M
A
D
IT
II
[8
•]
D
IN
A
M
IT
[9
•]
IR
IS
[1
0]
C
A
T
[1
1]
Y
ea
r
of
pu
bl
ic
at
io
n
19
99
20
02
20
04
20
09
20
02
Y
ea
rs
of
en
ro
llm
en
t
19
90
–1
99
7
19
97
–2
00
1
19
98
–2
00
2
19
99
–2
00
7
19
91
–9
7
P
ri
m
ar
y
pr
ev
en
tio
n
tr
ia
ls
–i
sc
ha
em
ic
ae
tio
lo
gy
P
ri
m
ar
y
pr
ev
en
tio
n
tr
ia
ls
–n
on
is
ch
ae
m
ic
or
m
ix
ed
ae
tio
lo
gy
T
ri
al
na
m
e
M
U
S
T
T
[7
]
M
A
D
IT
II
[8
•]
D
IN
A
M
IT
[9
•]
IR
IS
[1
0]
C
A
T
[1
1]
Y
ea
r
of
pu
bl
ic
at
io
n
19
99
20
02
20
04
20
09
20
02
Y
ea
rs
of
en
ro
llm
en
t
19
90
–1
99
7
19
97
–2
00
1
19
98
–2
00
2
19
99
–2
00
7
19
91
–9
7
In
cl
us
io
n
cr
ite
ri
a
C
A
D
+
PV
S-
in
du
ce
d
su
sV
T
P
re
vi
ou
s
M
I
(>
1
m
on
th
)
R
ec
en
tM
I
(6
–4
0
da
ys
)
+
C
A
F+
R
ec
en
tM
I
(5
–3
1
da
ys
)
an
d:
i)
LV
E
F
≤
40
%
an
d
H
R
≥
90
on
E
C
G
;O
R
ii)
ns
V
T
on
H
ol
te
r
N
IC
M
≤9
m
on
th
s
+
N
Y
H
A
II
or
II
I
LV
E
F
cu
t-
of
f
≤
40
%
≤
30
%
≤
35
%
A
s
ab
ov
e
≤
30
%
N
Y
H
A
cr
ite
ri
a
I
to
II
I
I
to
II
I
I
to
II
I
I
to
II
I
II
to
II
I
N
o.
ra
nd
om
is
ed
70
4
12
32
67
4
89
8
10
4
N
o.
(%
)
w
ith
N
IC
M
0
0
0
0
10
4
(1
00
)
Fo
llo
w
-u
p,
m
ea
n
(S
D
),
m
on
th
39
20
30
(1
3)
37
66
(2
6.
4)
D
em
og
ra
ph
ic
s
A
ge
,m
ea
n
(S
D
),
ye
ar
67
64
(1
0)
62
(1
1)
63
52
(1
1)
M
al
e,
%
(N
o.
)
90
84
(1
04
0)
76
(5
14
)
77
(6
89
)
80
(8
3)
N
Y
H
A
cl
as
s
II
I/
IV
,%
(N
o.
)
24
29
(3
55
)
13
(8
9)
12
(1
07
)
34
.6
(3
6)
D
ur
at
io
n
of
C
H
F,
m
ea
n
N
R
N
R
N
R
33
2
3
m
on
th
s
LV
E
F,
m
ea
n
(S
D
),
%
30
23
(5
)
28
(5
)
34
2
24
(7
)
M
ed
ic
at
io
ns
at
ba
se
lin
e,
%
(N
o.
)
67
4
A
C
E
in
hi
bi
to
r/
A
R
B
75
(5
25
)
70
(8
58
)
95
(6
38
)
82
(7
34
)
96
.2
(1
00
)
B
B
40
(2
82
)
70
(8
62
)
87
(5
85
)
87
(7
82
)
3.
8
(4
)
M
R
A
N
R
N
R
N
R
N
R
N
R
C
R
T
0
0
0
0
0
D
es
ig
n
E
PS
+
gu
id
ed
as
si
gn
m
en
t
to
IC
D
or
A
A
D
,o
r
st
an
da
rd
ca
re
if
ne
ga
tiv
e
E
PS
IC
D
vs
C
M
T
(3
:2
)
IC
D
vs
C
M
T
IC
D
vs
C
M
T
IC
D
vs
C
M
T
P
ri
m
ar
y
en
dp
oi
nt
C
A
or
ar
rh
yt
hm
ic
de
at
h
A
C
M
A
C
M
A
C
M
A
C
M
D
ef
ib
ri
lla
to
r
T
ra
ns
ve
no
us
/e
pi
ca
rd
ia
l,
%
N
R
10
0/
0
10
0/
0
10
0/
0
10
0/
0
In
te
rn
al
va
lid
ity
F
ol
lo
w
-u
p,
%
N
R
N
R
99
%
99
.9
%
10
0
C
ro
ss
ov
er
s
to
IC
D
,%
(N
o.
)
12
(n
/a
)
4.
5
(2
2)
0
8.
6
(3
9/
45
3)
N
R
C
ro
ss
ov
er
s
to
co
nt
ro
l%
(N
o.
)
n/
a
6
(4
4)
6
(2
0)
10
(4
5/
44
5)
N
R
T
ab
le
1
(c
on
tin
ue
d)
378 Curr Heart Fail Rep (2018) 15:376–389
T
ab
le
1
(c
on
tin
ue
d)
Pr
im
ar
y
pr
ev
en
tio
n
tr
ia
ls
–n
on
is
ch
ae
m
ic
or
m
ix
ed
ae
tio
lo
gy
T
ri
al
na
m
e
A
M
IO
V
IR
T
[1
2]
D
E
FI
N
IT
E
[1
3]
C
O
M
PA
N
IO
N
[1
4]
S
C
D
-H
eF
T
[1
5•
]
D
A
N
IS
H
[1
6•
]
Y
ea
r
of
pu
bl
ic
at
io
n
20
03
20
04
20
04
20
05
20
16
Y
ea
rs
of
en
ro
llm
en
t
19
96
–2
00
0
19
98
–2
00
2
20
00
–2
00
2
19
97
–2
00
1
20
08
–2
01
4
Pr
im
ar
y
pr
ev
en
tio
n
tr
ia
ls
–n
on
is
ch
ae
m
ic
or
m
ix
ed
ae
tio
lo
gy
T
ri
al
na
m
e
A
M
IO
V
IR
T
[1
2]
D
E
FI
N
IT
E
[1
3]
C
O
M
PA
N
IO
N
[1
4]
S
C
D
-H
eF
T
[1
5•
]
D
A
N
IS
H
[1
6•
]
Y
ea
r
of
pu
bl
ic
at
io
n
20
03
20
04
20
04
20
05
20
16
Y
ea
rs
of
en
ro
llm
en
t
19
96
–2
00
0
19
98
–2
00
2
20
00
–2
00
2
19
97
–2
00
1
20
08
–2
01
4
In
cl
us
io
n
cr
ite
ri
a
N
IC
M
+
N
Y
H
A
I
to
II
I+
as
ym
pt
om
at
ic
ns
V
T
N
IC
M
+
pr
ev
H
F
+
ns
V
T
or
≥
10
PV
C
s
pe
r
ho
ur
Q
R
S
in
te
rv
al
≥
12
0
m
s
+
PR
in
te
rv
al
≥
15
0
m
s
+
si
nu
s
rh
yt
hm
+
re
ce
nt
H
FH
A
s
pe
r
LV
E
F
an
d
N
Y
H
A
cr
ite
ri
a
be
lo
w
N
IC
M
+
N
T-
pr
oB
N
P
>
20
0
pg
/m
l
LV
E
F
cu
t-
of
f
≤
35
%
≤
35
%
≤
35
%
≤
35
%
≤
35
%
N
Y
H
A
cr
ite
ri
a
I
to
II
I
I
to
II
I
II
I
or
IV
II
or
II
I
II
or
II
I
(o
r
IV
if
C
R
T
pl
an
ne
d)
N
o.
ra
nd
om
is
ed
10
3
45
8
15
20
25
21
11
16
N
o.
(%
)
w
ith
N
IC
M
10
3
(1
00
)
45
8
(1
00
)
67
8
(4
5)
12
11
(4
8)
11
16
(1
00
)
Fo
llo
w
-u
p,
m
ea
n
(S
D
),
m
on
th
24
(1
4.
4)
29
(1
4)
R
an
ge
14
.8
–1
6.
0
45
.5
67
.6
(N
R
)
D
em
og
ra
ph
ic
s
A
ge
,m
ea
n
(S
D
),
ye
ar
59
(1
1.
5)
58
67
60
64
*
M
al
e,
%
(N
o.
)
70
(7
2)
71
(3
26
)
67
(1
02
5)
77
(1
93
3)
72
(8
09
)
N
Y
H
A
cl
as
s
II
I/
IV
,%
(N
o.
)
20
(2
0)
21
(9
6)
10
0
(1
52
0)
30
(7
60
)
47
(5
19
)
D
ur
at
io
n
of
C
H
F,
m
ea
n
3.
2
ye
ar
s
2.
8
ye
ar
s
3.
6
ye
ar
s
24
.5
m
on
th
s
19
(N
R
)*
LV
E
F,
m
ea
n
(S
D
),
%
23
(9
)
21
(1
4)
21
25
25
(N
R
)*
M
ed
ic
at
io
ns
at
ba
se
lin
e,
%
(N
o.
)
A
C
E
in
hi
bi
to
r/
A
R
B
85
(8
8)
96
.7
(4
43
)
89
(1
35
9)
96
(2
43
2)
97
(1
07
7)
B
B
51
.5
(5
3)
84
.9
(3
89
)
68
(1
02
7)
69
(1
73
8)
92
(1
02
6)
M
R
A
19
.4
(2
0)
N
R
54
(8
24
)
20
(5
07
)
58
(6
46
)
C
R
T
0
4.
8
(1
1)
in
IC
D
gr
ou
p;
N
R
in
co
nt
ro
ls
80
(1
21
2)
in
tr
ea
tm
en
tg
ro
up
s
N
R
58
(6
45
)
D
es
ig
n
IC
D
vs
am
io
.
IC
D
vs
C
M
T
C
R
T-
D
vs
C
R
T-
P
vs
C
M
T
IC
D
vs
am
io
.v
s
pl
ac
eb
o
IC
D
vs
C
M
T
Pr
im
ar
y
en
dp
oi
nt
A
C
M
A
C
M
A
C
M
/A
C
H
A
C
M
A
C
M
D
ef
ib
ri
lla
to
r
Tr
an
sv
en
ou
s/
ep
ic
ar
di
al
,%
10
0/
0
10
0/
0
10
0/
0
10
0/
0
10
0/
0
In
te
rn
al
va
lid
ity
Fo
llo
w
-u
p,
%
10
0
10
0
>
95
%
10
0
10
0
C
ro
ss
ov
er
s
to
IC
D
,%
(N
o.
)
15
.4
(8
)
10
(2
3)
26
(8
0)
††
N
R
4.
8
(2
7)
C
ro
ss
ov
er
s
to
co
nt
ro
l%
(N
o.
)
21
.6
(1
1)
1.
7
(4
)
N
R
N
R
7.
9
(4
4)
A
A
D
,a
nt
ia
rr
hy
th
m
ic
dr
ug
;A
C
E
,a
ng
io
te
ns
in
-c
on
ve
rt
in
g
en
zy
m
e;
A
C
H
,a
ll-
ca
us
e
ho
sp
ita
lis
at
io
n;
A
C
M
,a
ll-
ca
us
e
m
or
ta
lit
y;
A
m
io
.,
am
io
da
ro
ne
;A
R
B
,a
ng
io
te
ns
in
-r
ec
ep
to
r
bl
oc
ke
r;
B
B
,b
et
a-
bl
oc
ke
r;
C
A
,
ca
rd
ia
c
ar
re
st
;C
A
F
+
,p
os
iti
ve
ca
rd
ia
c
au
to
no
m
ic
fu
nc
tio
n
te
st
;C
H
F,
co
ng
es
tiv
e
he
ar
tf
ai
lu
re
;C
M
T,
co
nv
en
tio
na
lm
ed
ic
al
th
er
ap
y;
C
R
T-
D
,c
ar
di
ac
re
sy
nc
hr
on
is
at
io
n
th
er
ap
y
de
fi
br
ill
at
or
;C
R
T-
P,
ca
rd
ia
c
re
sy
nc
hr
on
is
at
io
n
th
er
ap
y
pa
ce
m
ak
er
;E
P
S+
,n
on
su
pp
re
ss
ib
le
ve
nt
ri
cu
la
r
ta
ch
ya
rr
hy
th
m
ia
on
el
ec
tr
op
hy
si
ol
og
ic
st
ud
y;
H
F
H
,h
os
pi
ta
lis
at
io
n
fo
r
he
ar
tf
ai
lu
re
;I
C
D
,i
m
pl
an
ta
bl
e
ca
rd
io
ve
rt
er
de
fi
br
ill
at
or
;
LV
E
F,
le
ft
ve
nt
ri
cu
la
re
je
ct
io
n
fr
ac
tio
n;
M
R
A
,m
in
er
al
oc
or
tic
oi
d
re
ce
pt
or
an
ta
go
ni
st
;N
IC
M
,n
on
-i
sc
ha
em
ic
ca
rd
io
m
yo
pa
th
y;
N
R
,n
ot
re
po
rt
ed
;N
YH
A
,N
ew
Y
or
k
H
ea
rt
A
ss
oc
ia
tio
n;
SA
E
+
,a
bn
or
m
al
iti
es
on
a
si
gn
al
-a
ve
ra
ge
d
el
ec
tr
oc
ar
di
og
ra
m
;
P
V
S,
pr
og
ra
m
m
ed
ve
nt
ri
cu
la
r
st
im
ul
at
io
n;
AV
ID
,A
nt
ia
rr
hy
th
m
ic
s
V
er
su
s
Im
pl
an
ta
bl
e
D
ef
ib
ri
lla
to
rs
;C
A
SH
,C
ar
di
ac
A
rr
es
tS
tu
dy
H
am
bu
rg
T
ri
al
;C
ID
S,
C
an
ad
ia
n
Im
pl
an
ta
bl
e
D
ef
ib
ri
lla
to
rS
tu
dy
;M
A
D
IT
,M
ul
tic
en
tr
e
A
ut
om
at
ic
D
ef
ib
ri
lla
to
rI
m
pl
an
ta
tio
n
T
ri
al
;M
A
D
IT
II
,S
ec
on
d
M
ul
tic
en
tr
e
A
ut
om
at
ic
D
ef
ib
ri
lla
to
rI
m
pl
an
ta
tio
n
T
ri
al
;D
IN
A
M
IT
,D
ef
ib
ri
lla
to
ri
n
A
cu
te
M
yo
ca
rd
ia
l
In
fa
rc
tio
n
T
ri
al
;
IR
IS
,I
m
m
ed
ia
te
R
is
k
S
tr
at
if
ic
at
io
n
Im
pr
ov
es
S
ur
vi
va
l
T
ri
al
;
C
A
B
G
-P
at
ch
,C
or
on
ar
y
A
rt
er
y
B
yp
as
s
G
ra
ft
Pa
tc
h
T
ri
al
;
M
U
ST
T,
M
ul
tic
en
tr
e
U
ns
us
ta
in
ed
Ta
ch
yc
ar
di
a
T
ri
al
;
A
M
IO
V
IR
T,
A
m
io
da
ro
ne
V
er
su
s
Im
pl
an
ta
bl
e
C
ar
di
ov
er
te
r-
D
ef
ib
ri
lla
to
r;
C
AT
,C
ar
di
om
yo
pa
th
y
T
ri
al
;D
E
F
IN
IT
E
,D
ef
ib
ri
lla
to
rs
in
N
on
-I
sc
ha
em
ic
C
ar
di
om
yo
pa
th
y
T
re
at
m
en
tE
va
lu
at
io
n
T
ri
al
;S
C
D
-H
eF
T,
T
he
S
ud
de
n
C
ar
di
ac
D
ea
th
in
H
ea
rt
Fa
ilu
re
T
ri
al
;C
O
M
PA
N
IO
N
,T
he
C
om
pa
ri
so
n
of
M
ed
ic
al
T
he
ra
py
,P
ac
in
g,
an
d
D
ef
ib
ri
lla
tio
n
in
H
ea
rt
Fa
ilu
re
;D
A
N
IS
H
,D
an
is
h
S
tu
dy
to
A
ss
es
s
th
e
E
ff
ic
ac
y
of
IC
D
s
in
P
at
ie
nt
s
w
ith
N
on
-i
sc
he
m
ic
S
ys
to
lic
H
ea
rt
F
ai
lu
re
on
M
or
ta
lit
y
*C
al
cu
la
te
d
as
m
ea
n
of
st
at
ed
m
ed
ia
ns
fo
r
tr
ea
tm
en
ta
nd
co
nt
ro
lg
ro
up
s
†
F
or
A
V
ID
,c
ro
ss
ov
er
ra
te
s
ar
e
re
po
rt
ed
at
2
ye
ar
s
†
†
Fo
r
C
O
M
PA
N
IO
N
,r
at
e
of
w
ith
dr
aw
al
fr
om
m
ed
ic
al
th
er
ap
y
gr
ou
p
is
re
po
rt
ed
as
cr
os
so
ve
r
ra
te
**
R
an
do
m
is
ed
to
IC
D
,a
m
io
da
ro
ne
,o
r
m
et
op
ro
lo
l(
no
tp
ro
pa
fe
no
ne
)
**
*N
on
-d
ef
ib
ri
lla
to
r
gr
ou
p
T
ab
le
1
(c
on
tin
ue
d)
Curr Heart Fail Rep (2018) 15:376–389 379
(hazard ratio [HR] 0.62, 95% confidence intervals [CI] 0.47–
0.81, p < 0.02). This reduction in all-cause mortality (ACM)
was driven by a reduction in SCD (HR 0.43, 95%CI 0.27–
0.66). The Cardiac Arrest Study Hamburg (CASH) trial en-
rolled 3461 patients resuscitated from cardiac arrest due to VT/
VF, randomising them to receive an ICD or one of three
AADs: amiodarone, metoprolol or propafenone [3]. Finally,
the Canadian Implantable Defibrillator Study (CIDS) recruit-
ed 659 patients who had experienced VT/VF associated with
one of five eligible clinical presentations (see Table 1) [4].
Patients were randomised to an ICD or amiodarone in a 1:1
ratio. Neither CASH nor CIDS demonstrated a significant
reduction in ACM with ICD therapy, although treatment with
a defibrillator was associated with a lower risk of SCD in
CASH (HR 0.32, 95%CI 0.15–0.69).
One thousand eight hundred sixty-six participants from
AVID, CIDS and CASH were subsequently combined in a
patient-level meta-analysis evaluating the effects of
randomisation to an ICD versus amiodarone or sotalol (thus
excluding the 97 patients allocated to metoprolol in CASH)
[17•]. Treatment with an ICD conferred a lower risk of ACM
(HR 0.73, 95%CI 0.60–0.87, p < 0.001), with this effect being
driven by a reduction in SCD (HR 0.49, 95%CI 0.36–0.67,
p < 0·001). There was no significant difference in non-sudden
mortality between the groups. The treatment effect of an ICD
was consistent across the three trials (p value for interaction =
0.306), suggesting that CIDS and CASH provide supportive
evidence for, rather thanmilitating against, the survival benefit
seen in AVID. Another meta-analysis of the secondary pre-
vention trials which included an additional small Dutch study
estimated a relative risk of ACM of 0.75, (95%CI 0.64–0.87,
p = 0·0002) [18].
These trials form the basis for international guideline rec-
ommendations [19, 20] for secondary prevention ICDs, in-
cluding those from the European Society of Cardiology
(ESC) and a combined guideline from the American College
of Cardiology (ACC), American Heart Association (AHA)
and the Heart Rhythm Society (HRS). Selected recommenda-
tions from these guidelines are summarised and contrasted in
Fig. 1.
As to precisely who benefits from a secondary prevention
ICD, there is little more to add. Exploration of subgroups in
the first meta-analysis described above found no interaction
between treatment effect and index VA, prior MI, non-
ischemic aetiology, coronary artery disease, New York Heart
Association (NYHA) functional class or coronary artery by-
pass at baseline. However, two significant subgroup interac-
tions were identified. First, patients treated with an ICD during
the ‘epicardial era’—defined as ending on 1st July 1991 –
derived less benefit from a defibrillator than those randomised
after this date, who largely received transvenous systems (P
for interaction = 0.029). Although this effect is likely con-
founded by other advances in management pre- and post-
1991, the proposition that transvenous ICDs should be supe-
rior to epicardial systems—which require a thoracotomy—is
patently plausible. Today, epicardial ICDs are seldom im-
planted. Second, patients with LVEF ≤ 35% derived signifi-
cantly more benefit from a defibrillator than those with LVEF
> 35% (P for interaction = 0.011), in whom there was a non-
significant trend towards harm (HR 1.2, 95%CI 0.81–1.76).
The CASH trial—in which more than half of patients received
an epicardial system—enrolled a population with a signifi-
cantly higher mean LVEF than AVID or CIDS (46% vs 31%
and 34% respectively). It is therefore possible that the lower
efficacy of an ICD detected in the LVEF > 35% group was
actually due to more frequent epicardial ICD use in this pop-
ulation. In any case, subgroup analyses must obviously be
treated with caution: consequently, international guideline rec-
ommendations for secondary prevention ICDs do not differ-
entiate according to LVEF, and further evidence from prospec-
tive studies would be required before this would change.
A final point of interest is that, in this meta-analysis, the
incremental separation over time of the Kaplan-Meier curves
for arrhythmic death contrasts with the lack of progressive
divergence between the curves for ACM, which initially sep-
arates before starting to converge after 4 years. Although this
suggested that the benefit of an ICD might wane over a longer
period, further insight is curtailed by the relatively short
follow-up in AVID and CIDS.
Who Benefits From a Primary Prevention
Defibrillator?
Acute MI: Late Implantation of an ICD
The quest to identify further patient groups which might
benefit from an ICD led next to primary prevention trials
in patients with a history of acute myocardial infarction
(AMI). At the time—approximately three decades ago—4
to 5-year mortality following hospital discharge after AMI
was ≥ 20% amongst patients with LVSD [21–23], with
SCD accounting for roughly one third of late mortality
[21, 24]. Seminal amongst these new trials was the
Second Multicentre Automatic Defibrillator Implantation
Trial (MADIT II) [8•]. Although three prior RCTs [5–7]
had examined the benefit of an ICD in patients with CAD
and/or MI, all had required the presence of VT and/or an
abnormal signal-averaged electrocardiogram (SAECG)
(see Table 1). Inclusion criteria for the original
Multicentre Automatic Defibrillator Implantation Trial
1 Assignment to propafenone was terminated early due to increased mortality
after 58 patients had been randomised to this arm, with results thus reported for
the remaining 288 patients in the defibrillator, amiodarone and metoprolol
arms.
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(MADIT I), for example, had included not merely LVSD
and a prior AMI, but also asymptomatic non-sustained VT
and inducible, non-suppressible VT on an electrophysiol-
ogy (EP) study. These predecessor trials were thus less
pragmatic and less broadly applicable than MADIT II, in
which eligible patients had experienced an AMI 1 month
or more prior to enrolment (although in three-quarters of
patients the gap was 18 months prior or longer, as shall be
discussed later), had an LVEF ≤ 30%, and had not under-
gone coronary revascularisation within the preceding
3 months. Participants were assigned in a 3:2 ratio to
receive either an ICD (n = 742) or conventional medical
therapy (CMT) (n = 490), amongst whom only 10% were
prescribed amiodarone.
During a mean follow-up of 20 months, the rates of
ACM were 14.2% and 19.8% in the ICD and CMT
groups respectively, with an ICD conferring a 31% rela-
tive reduction in the risk of death (HR 0.69, 95%CI 0.51–
0.93, p = 0.016). The effect of ICD therapy on survival
did not vary according to any of the subgroups analysed,
including those defined by age, sex, LVEF, NYHA class,
QRS duration, diabetes, left bundle-branch block or atrial
fibrillation. The survival benefit was entirely due to a
reduction in SCD, consistent with the plausible benefit
of a def ibr i l la tor (HR 0.33, 95%CI 0.20–0.53,
p < 0.0001) [25]. Notably, although the cumulative hazard
curves reflecting SCD separated early, those for ACM
diverged only after ~ 9 months. This effect appears to
have been driven by a trend towards increased non-
sudden cardiac death within the ICD group, especially
during the first year, although this did not reach statistical
significance. There was also a trend to new or worsening
HF in the ICD group.
Acute MI: Early Implantation of an ICD
Patients within 1 month of an AMI were excluded from
MADIT II. Two subsequent RCTs—the Defibrillator in
Acute Myocardial Infarction Trial (DINAMIT) and
Immediate Risk Stratification Improves Survival (IRIS)
trial—thus sought to examine the effect of an ICD in
patients following a recent AMI (6–40 days and 5–
31 days post-MI respectively) [9•, 10]. Outline charac-
teristics of both trials are presented in Table 1.
Eligibility criteria for DINAMIT included LVEF ≤ 35%
and impaired cardiac autonomic function, with patients
randomised to medical therapy with (n = 332) or without
(n = 342) a defibrillator. After an average follow-up of
30 months, there was a 58% lower risk of SCD in the
ICD group when compared to the control group (HR
0.42, 95%CI 0.22–0.83, p = 0.009), with 12 and 29 sud-
den deaths respectively in these groups. An ICD did not
confer an overall mortality benefit however, due to a
significant increase in non-sudden cardiac deaths in the
ICD group (HR 1.75, 95%CI 1.11–2.76, p = 0.02). IRIS
required eligible patients to have LVEF ≤ 40% and a
heart rate ≥ 90 beats per minute or non-sustained VT
on Holter monitor, randomising them to medical therapy
Patients * † with IHD or NICM:
i) SCA due to VT/VF; OR
ii) hemodynamically unstable VT; OR
iii) stable VT
Patients * with IHD: 
i) Unexplained syncope + inducible 
susVT on EPS
EPS = electrophysiology study
ICD = implantable cardioverter defibrillator 
IHD = ischaemic heart disease
LVEF = left ventricular ejection fraction
MI = myocardial infarction
NICM = nonischaemic cardiomyopathy
NYHA = New York Heart Association
SCA = sudden cardiac arrest 
susVT = sustained monomorphic ventricular tachycardia
* Provided meaningful survival >1 year is expected.
† Where not due to a reversible cause
‡ Receiving optimal medical therapy
§ After 3 months of optimal medical therapy
¶ Where not within 48 hours of a myocardial infarction 
Any patients ‡ ¶ * with: 
i) VF; OR 
ii) hemodynamically  VT
Any patients ‡ ¶ * with: 
i) recurrent susVT + normal LVEF
Recommendations for primary prevention ICDs
Patients * ‡ with IHD:
i)
ii)
40 days post-MI; AND
90 days post-revascularisation; AND
iii) LVEF ≤35% + NYHA functional class II –III; OR
iv) LVEF ≤30% + NYHA functional class I
Patients § with IHD:
i) LVEF 
ii)   6 weeks after acute MI
35% + NYHA class II–III
Patients * ‡ with NICM:
i) LVEF ≤35% + NYHA functional class II –III
Patients * ‡ with NICM:
i) LVEF ≤35% + NYHA functional class I
Patients § with NICM:
i) LVEF 35% + NYHA class II–III
Recommendations for secondary prevention ICDs
2017 ACC / AHA / HRS guideline 
recommendations
2015 ESC guideline 
recommendations
CoR I; LoE B-R to B-NR
CoR I; LoE AICD is
recommended
CoR I; LoE B-NR
ICD is
recommended
CoR IIa; LoE C
ICD 
should be 
considered
ICD is
recommended
CoR I; LoE A
CoR I; LoE A
CoR IIb; LoE B-R
ICD is
recommended
ICD is
recommended
ICD may be 
considered
CoR I; LoE A
CoR I; LoE B
ICD is
recommended
ICD is
recommended
CoR = class of recommendation
LoE = level of evidence
B-R = level of evidence B, base on randomised trial data
B-NR = level of evidence B, base on non-randomised trial data
Fig. 1 Selected international guideline recommendations for implantable cardioverter defibrillators
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with (n = 445) or without (n = 453) a defibrillator.
During an average follow-up of 37 months, there was
a lower risk of sudden death with an ICD (HR 0.55,
95%CI 0.31–1.00, p = 0.049) that, as in DINAMIT, was
offset by an increase in non-sudden cardiac death
amongst ICD recipients (HR 1.92, 95%CI 1.29–2.84,
p = 0.001). Resultantly, there was no difference in
ACM between the two groups.
This increase in non-sudden death associated with an ICD
in DINAMITand IRIS is partially explained by the competing
risks posed by multiple potential causes of death. In the ICD
groups, the reduction in SCD associated with a defibrillator
led to a larger pool of survivors at risk of non-sudden death
when compared to the control groups. That is, treatment with
an ICD may have merely switched the mode of death from
arrhythmic to non-arrhythmic (presumably deaths due to is-
chaemia or heart failure since the difference in non-sudden
events was driven by cardiac causes). This is why ACM—
rather than SCD—is the more appropriate primary endpoint
for a trial examining the benefit of a defibrillator.2 Of course,
this principle is true of other ICD trials, yet in several increases
in non-sudden death were not sufficiently great to offset the
concomitant reductions in SCD afforded by an ICD. For ex-
ample, non-sudden cardiac death increased in the ICD arm of
MADIT II (4.3% of deaths in the control group, compared to
5.8% of deaths in the ICD group) without nullifying the over-
all survival benefit of an ICD.
Closer inspection of these trials is instructive. In both
DINAMIT and IRIS, clinical events were classified by adju-
dication committees blinded to treatment assignment; there
were few significant differences between the ICD and control
group characteristics, and neither trial experienced high cross-
over rates between treatments. Artefact was therefore unlikely
to have substantially contributed to the results. The first major
difference in inclusion criteria between DINAMIT/IRIS and
other primary prevention trials carried out in patients with
ischemic heart disease (IHD) was the use of autonomic func-
tion and heart rate criteria in the former (depressed heart-rate
variability or elevated 24-h heart rate in DINAMIT and ele-
vated heart rate or non-sustained VT in IRIS). Subsequent
research suggests that these phenomena are associated with
an increased risk of ACM rather than specifically arrhythmic
SCD [26, 27]. Thus, whereas the investigators had intended
these criteria to select participants at particularly high risk of
arrhythmic death, they may have inadvertently enriched the
study populations with patients also at high risk of non-sudden
cardiac death, thus increasing the probability that patients
‘saved’ from arrhythmic death by an ICD would nevertheless
die from an alternative cardiac cause soon after.
The second major difference in inclusion criteria between
DINAMIT/IRIS and other primary prevention trials per-
formed in IHD populations was the temporal proximity to
index AMI. This temporal difference is more substantial than
might be assumed a priori from inclusion criteria. For exam-
ple, although MADIT II ostensibly recruited patients who
were at least 1 month remote from an AMI, in reality, this
period was 81 months on average, and greater than 6 months
in nearly 90% of patients [28]. The subpopulation of
DINAMIT and IRIS patients who died during the early post-
AMI period were thus not meaningfully represented in
MADIT II. This survivorship bias is important because this
cohort is likely to have had a particularly vulnerable cardiac
substrate, susceptible not merely to ventricular arrhythmias
but to other causes of cardiac death. By comparison, it may
be presumed that patients in other primary prevention RCTs
had more compensated, remodelled hearts that were suscepti-
ble to scar-related VAs but at relatively lower competing risk
of imminent reinfarction or heart failure. Substantiating this, a
subgroup analysis of MADIT-II found that although mortality
risk increased as a function of time fromMI, randomisation to
an ICD only conferred a survival benefit in those patients ≥
18 months remote from their qualifying MI (HR 0.55, 95%CI
0.39–0.78, p = 0.001) versus those with relatively recent MI
(< 18 months; HR 0.97, p = 0.92), with this benefit remaining
substantial for ≥ 15 years post-infarct [28].
A further, more troubling possibility is that ICDs might
increase non-arrhythmic mortality not merely indirectly, by
‘switching’ the mode of death, but directly, via intrinsically
deleterious mechanisms. This relates less to peri-procedural
deaths—of which there was only one in IRIS and none in
DINAMIT—but rather the consequences to the myocardium
of high voltage defibrillation therapy. Early signals of this
possibility were that randomisation to a defibrillator was as-
sociated with an increased risk of rehospitalisation in AVID,
and with a higher rate of new or worsening heart failure in
MADIT II. Subsequent analyses of several ICD trials, includ-
ing DINAMIT and MADIT II, demonstrated an association
between ICD shocks (both appropriate and inappropriate) and
ACM [25, 29, 30]. Evidence supporting a causative relation-
ship arrived with the publication of the Multicenter Automatic
Defibrillator Implantation Trial–Reduce Inappropriate
Therapy (MADIT-RIT) s tudy in 2012, in which
randomisation to either of two novel ICD programming
modes—both of which reduced appropriate and inappropriate
ICD therapy— resul ted in lower ACM than with
randomisation to conventional ICD programming (which
was most similar to the ICD programming used in the RCTs
discussed above) [31•].
The question of who might benefit from receiving an ICD
within 40 days of MI is currently being readdressed in the
PROTECT-ICD trial (see Table 2). In the intervention arm
of the trial, patients within 2–40 days of an MI will undergo
2 It was due to this realisation that, midway through the CIDS trial, the
Steering Committee revised the primary outcome measure from arrhythmic
death to ACM
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an EP study, whereby those with inducible VTwill receive an
ICD, and those without shall not. Participants will alternative-
ly be randomised to a control arm (standard care). In a sub-
study of the trial, cardiac magnetic resonance (CMR) imaging
will be performed, for correlation of CMR data with the pres-
ence of inducible VT at EP study and clinical outcomes. The
primary endpoint of the trial is SCD or non-fatal arrhythmia,
which may garner criticism given the issues discussed above.
Patients Undergoing Coronary Artery Bypass Grafting
The Coronary Artery Bypass Grafting Patch (CABG-Patch)
trial examined whether an ICD could reduce mortality in pa-
tients undergoing coronary artery bypass graft (CABG) sur-
gery [6]. Eligible patients were already scheduled for CABG
and required to have LVEF ≤ 35% and abnormalities on an
SAECG. Nine hundred participants were randomised to peri-
operative implantation of an epicardial ICD or standard care in
a 1:1 ratio. During an average follow-up of 32 months, there
were 101 deaths from any cause in the ICD group and 95 in
the control group (HR 1.07, 95%CI 0.81–1.42). This was
despite a borderline significant reduction in SCD with an
ICD (HR 0.55, 95%CI 0.29–1.03; p = 0.06). Underlying this,
SCD comprised just 29% of all deaths in the control group
(compared to, for example, 49%, 50% and 51% inMADIT II,
DINAMIT and IRIS respectively). Resultantly, it was more
challenging for a defibrillator to significantly reduce SCD,
and harder still for any such reduction to affect ACM. The
explanation for this low rate of SCD is not certain. However,
it was notable that the difference in the rates of SCD between
the groups increased with duration of follow-up, with the
Kaplan-Meier curves for SCD separating after ~ 6 months
and diverging progressively over the follow-up period. A pos-
sible explanation is that revascularisation at the time of
randomisation temporarily negated a potent substrate for ar-
rhythmic death, since it has been estimated that 35–58% of
SCD is preceded by myocardial ischaemia [32, 33]. By con-
trast, revascularisation was not universal inMADIT II, IRIS or
DINAMIT, with a third of patients in DINAMIT receiving no
revascularisation following their index MI. The implication is
that, without a method to more precisely identify patients at
high risk of SCD post-CABG, the rate of fatal VA in this
population is too low to warrant a broad indication for a
peri-operative defibrillator implantation. Because the rate of
SCD increased as a function of time from revascularisation in
CABG-Patch—presumably due to the development of graft
failure—it would seem logical for a follow-up trial to have
examined the potential benefit of an ICD in patients more
remote from their index surgical procedure. However, a large
proportion of this population was represented in the subse-
quent MADIT II trial, in which over half of patients had a
previous CABG, thus diluting this impetus.
Patients with Heart Failure and Reduced Ejection
Fraction (HFrEF)
The Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)
was the first RCT to examine whether an ICD would reduce
the risk of death in a population with chronic heart failure and
reduced ejection fraction (HFrEF) of either ischemic or non-
ischemic aetiology (see Table 1 for trial characteristics) [15•].
The investigators also sought to determine whether the effica-
cy of an ICD was influenced by heart failure symptom sever-
ity. Two thousand five hundred twenty-one patients in NYHA
functional classes II to III were randomised to placebo, amio-
darone or an ICD. Over a median follow-up of 46 months,
ICD treatment reduced ACM by 23% compared to placebo
(HR 0.77, 97.5% CI 0.62–0.96, p = 0.007). The survival ben-
efit conferred by an ICD did not differ according to ischemic
or non-ischemic aetiology (P for interaction = 0.68), implying
a survival advantage in patients with NICM. This benefit was
maintained for patients in NYHA functional class II (HR 0.54,
97.5% CI 0.40–0.74, p < 0.001), but not for those in NYHA
class III (P for interaction < 0.001). One potential explanation
for this finding is that the competing risk of pump failure death
in NYHA functional class III patients was too substantial for
ICDs to reduce overall mortality. This possibility is supported
by other studies in which patients with more advanced symp-
toms were more likely to die from pump failure than SCD
[34–36]. However, the HR for SCD and other cardiovascular
death (CVD) subtypes stratified by NYHA class were not
published, and moreover, this finding was not replicated in
MADIT II, in which there was no interaction between treat-
ment effect and NYHA class [37].
The survival benefit of an ICD in relation to NYHA class
was examined further in a recent patient-level meta-analysis of
four primary prevention trials [38]. For the 1867 patients in
NYHA class II, an ICD was associated with a reduction in
ACM (HR 0.55, 95%CI 0.35–0.85). ACM was not signifi-
cantly reduced for ICD-treated patients in NYHA class III
(HR 0.76, 95%CI, 0.48–1.24); however, there were substan-
tially fewer patients in this subgroup (n = 896), and the point
estimate suggests a significant effect might have been proven
had the group been larger. To add context to this issue, the
distinction between NYHA functional classes is subjective,
and individual patients within the same NYHA class may be
at substantially different risk of sudden and non-sudden death
according to other important characteristics, such as LVEF
and the presence of severe comorbidity. Appropriately, inter-
national guidelines regarding primary prevention ICDs make
no overriding distinction between recommendations for pa-
tients in NYHA functional class II or III (see Fig. 1).
However, it is widely assumed that patients in NYHA class
IVare at too high risk of pump failure death to benefit from an
ICD. These patients were largely excluded from the above
trials.
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The Comparison of Medical Therapy, Pacing, and
Defibrillation in Heart Failure (COMPANION) trial
randomised 1520 patients with HFrEF to CMT alone or in
combination with either a cardiac resynchronisation pacemak-
er (CRT-P) or cardiac resynchronisation defibrillator (CRT-D)
[14]. Patients were in either NYHA functional classes III or
IV, and both ICM and NICM patients were included. Across
the trial population, assignment to CRT-Dwas associated with
a 36% reduction in ACM when compared to CMT (HR 0.64,
95%CI 0.48–0.86, p = 0.003). This was driven in part by a
56% reduction in SCD (HR for CRT-D vs CMT 0.44,
95%CI 0.23–0.86, p = 0.02). It should be noted that these
HRs incorporate the extra mortality benefit of randomisation
to CRT in addition to that derived from a defibrillator.
Specifically, amongst patients with NICM, CRT-D therapy
led to a lower risk of ACM, as compared with CMT (HR
0.50, 95%CI 0.29–0.88). There was no interaction between
ischemic/non-ischemic aetiology of HFrEF and the survival
benefit of CRT-D over pharmacologic therapy.
Patients with HFrEF and a Presumed Non-ischemic
Aetiology: the Pre-DANISH Era
The first two primary prevention ICD trials (the
Cardiomyopathy Trial (CAT) and Amiodarone Vs
Implantable Cardioverter-Defibrillator (AMIOVIRT) trial) fo-
cussing on non-ischemic cardiomyopathy (NICM) were
stopped early for futility, resulting in part from mortality rates
that were far lower than anticipated [11, 12]. In CAT, for
example, the rate of ACM after 12 months was just 5.6% in
the control group, and although final rates of SCD were not
reported, none occurred during the first 2 years. The
Defibrillators in Non-Ischemic Cardiomyopathy Treatment
Evaluation (DEFINITE) trial subsequently assigned 458 pa-
tients with NICM to medical therapy with or without a prima-
ry prevention ICD. Assignment to an ICD reduced SCD (HR
0.20, 95%CI 0.06–0.71, p = 0.006), but ACM was not signif-
icantly different between the groups (HR 0.65, p = 0.08) [13].
This was because the incidence of SCD was lower than antic-
ipated, comprising 35% of all deaths in the control group.
Over a mean follow-up of 29 months, there were only 68
deaths from any cause. Results from the SCD-HeFT and
COMPANION trials involving subgroups with NICM are
discussed above.
The CAT, AMIOVIRT, DEFINITE and SCD-HeFT and
COMPANION trials were subsequently combined in a meta-
analysis, which was until recently the most robust evidence
available regarding the efficacy of ICDs in NICM [39].
Pooled analysis indicated a reduction in ACM amongst pa-
tients randomised to a defibrillator (either ICD or CRT-D)
when compared to medical therapy (HR 0.69, 95%CI 0.55–
0.87, p = 0.002). It is important to note that the data utilised in
this meta-analysis from COMPANION were a comparison of
CRT-D and medical therapy, since the effect of CRT-D versus
CRT-P was not available at the time.3 Since CRT reduces both
SCD and other forms of death in patients with heart failure
[40], the perceived efficacy of a defibrillator in this analysis
may have been overestimated by the concomitant benefit of
CRT.
Despite the lack of an RCT showing outright benefit of an
ICD in patients with NICM, current ESC guideline recom-
mendations for primary prevention ICDs in patients with
HFrEF (published 2015 and based on MADIT II, SCD-
HeFT, DEFINITE and the meta-analysis discussed above)
vary little according to ischemic/non-ischemic aetiology (see
Fig. 1). The ACC/AHA/HRS guidelines were published in
2017, subsequent to the results of the DANISH trial, which
is discussed next.
Patients with HFrEF and a Presumed Non-ischemic
Aetiology: the DANISH Trial
The largest and most recent primary prevention ICD trial in
patients with NICM was the Danish Study to Assess the
Efficacy of ICDs in Patients with Non-ischemic Systolic
Heart Failure on Mortality (DANISH) [16•]. DANISH
randomised 1116 patients to optimal medical therapy with or
without a defibrillator in a 1:1 allocation. After a median
follow-up period of 5.6 years, ACM did not differ significant-
ly between the defibrillator and control groups, in which there
were 120 and 131 deaths respectively (HR, 0.87, p = 0.28),
despite the fact that an ICD conferred a 50% reduction in the
risk of SCD (HR 0.50, 95%CI 0.31–0.82, p = 0.005).
What can we learn from DANISH? In this contemporary
trial, SCD constituted 35% of overall mortality in the control
group, matching the proportion found in DEFINITE.
However, whilst the annual mortality rate in DEFINITE was
low at 7%, it was just 5% in DANISH. Resultantly, there were
only 70 sudden deaths overall, with the rate of SCD in the
control group less than 2% per year. This means the absolute
reduction in SCD was just 3.9% during a follow-up of more
than 5 years. More broadly, CVD comprised only 73% of
ACM amongst patients in the control group, a relatively small
proportion when set against older ICD trials, and heart failure
trials more generally (82% in MADIT II, for instance).
Underlying these low mortality rates, the use of neurohor-
monal antagonist drugs with prognostic benefit in heart failure
was high in DANISH, with angiotensin-converting enzyme
(ACE) inhibitors or angiotensin II receptor blockers (ARBs),
beta-blockers and mineralocorticoid receptor antagonists
(MRAs) prescribed to 97%, 92% and 58% of patients respec-
tively. In parallel, 58% of patients in both treatment arms were
3 Recently, a comparison of the CRT-D and CRT-P arms from COMPANION
was published [43•]: the HR for ACMwas 0.84 (95%CI 0.65–1.09), for CVD
it was 0.73 (95%CI 0.55–0.98) and for SCD it was 0.37 (95%CI 0.21–0.65).
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receiving cardiac resynchronisation therapy (CRT). In patients
with heart failure, these pharmacologic therapies and CRT
each additively reduce the risk of both SCD and pump failure
death, and indeed of CVDmore generally. As these treatments
are increasingly more prevalent, rates of both sudden and car-
diovascular death are falling across RCTs enrolling patients
with heart failure [41, 42]. Resultantly, in an optimally treated
trial population, even a large reduction in SCD may fail to
significantly impact overall mortality if SCD is a relatively
small proportion of CVD, and CVD is in turn a relatively
small proportion of ACM. For trialists seeking to show that
an ICD—a treatment which reduces SCD but not other modes
of death—confers an overall survival benefit, this increases
the challenge.
In this context, recent analysis of patients receiving the
most optimal medical therapy in COMPANION yields a sa-
lient observation [43•]. Across the entire trial cohort, the re-
ductions in ACM with CRT-D and CRT-P when each was
compared to CMT were 36% and 24% respectively (CRT-D
vs CMT: HR 0.64, 95%CI 0.48–0.86; CRT-P vs CMT: HR
0.76, 95% CI 0.57–1.01). However, amongst patients receiv-
ing two neurohormonal antagonists (ACE-inhibitor or ARB,
plus beta-blocker; ~ 61% of patients in COMPANION), the
difference in treatment efficacy between CRT-D and CRT-P
was abolished (CRT-D vs CMT: HR 0.56, 95%CI 0.37–0.85;
CRT-P vs CMT: HR 0.57, 95%CI 0.37–0.85). A similar trend
was evident in the much smaller subgroup of patients who
were additionally receiving an MRA. The implication is that
in the best-treated patients, a defibrillator confers no incre-
mental benefit on top of CRT plus optimal medical therapy.
This is supported by a recent meta-analysis of COMPANION
and DANISH, in which there was no significant difference in
ACM between patients randomised to CRT-P or CRT-D [44].
A declining rate of CVD associated with optimal medical
therapy also lends greater weight to the contribution of non-
cardiovascular death to ACM. Since comorbidity associates
with older age, a proportionately greater incidence of non-
cardiovascular death is liable to emerge in trials with longer
follow-up and lower CVD, such as DANISH. In keeping with
this, there was a significant interaction between age and the
treatment effect of an ICD inDANISH, with benefit suggested
for patients in the younger two tertiles, but not in the older
tertile: age < 59 years (HR 0.51, 95%CI 0.29–0.92), age ≥ 59
to < 68 years (HR 0.75, 95%CI 0.48–1.16) and ≥ 68 years
(HR 1.19, 95%CI 1.19–1.73) (P for interaction = 0.009).
Moreover, the investigators reported that the proportional haz-
ard assumption for ACM was violated (p = 0.054 when tested
with Schoenfeld residuals), implying that the benefit derived
from treatment with an ICD varied as the trial progressed.
Reflecting this, the Kaplan-Meier curves diverged during the
first 5 years, before converging and eventually crossing after
~ 7.5 years. In totality, this suggests that ICDs reduce overall
mortality in younger patients before the development of
worsening heart failure and/or non-cardiovascular comorbid-
ity, leading to an increasing risk of non-sudden death. A recent
pre-specified subgroup analysis by the DANISH investigators
further examined the interaction between age and ICD benefit
[45]. This demonstrated that with an ICD, each year of youn-
ger age was associated with a 3.0% (95%CI, 0.03–6.0; p =
0.03) lower relative risk of ACM, with the point estimate
crossing unity at ~ 70 years of age. When dichotomised, pa-
tients ≤ 70 years of age had significantly better survival with
an ICD (HR, 0.70; 95%CI, 0.51–0.96; p = 0.03) whereas those
> 70 years old did not (HR 1.05; p = 0.84). The rates of sudden
and non-sudden death in the control group were 1.8 and 2.7
events per 100 patient-years respectively in those aged ≤
70 years. In contrast, they were 1.6 and 5.4 events per 100
patient-years respectively for those aged > 70 years.
Where Do We Go From Here?
The DANISH trial reminds us that the evolution of pharmaco-
logic therapy and CRT has altered the landscape in which
trialists seek to prove a survival benefit with ICD therapy.
Only where there is a sufficiently high risk of arrhythmic death,
and concomitantly low risk of all other forms of death, can the
capacity for ICDs to reduce SCD translate into an observable
reduction in ACM.But themajority of patients with heart failure
and/or LVSD no longer die from arrhythmic causes, and CVD
has also proportionally declined, resulting in non-cardiovascular
mortality playing an increasingly prominent role. Insights from
DANISH affirm that increasing age and the development of
comorbidity identify patients at higher risk of non-sudden death
i.e. those less likely to benefit from a defibrillator. As time
moves on, so competing risks of death emerge. In this regard,
the much shorter follow-up periods employed in earlier ICD
trials are notable: in MADIT II and COMPANION for instance,
the durations of follow-up were just 20 and ~ 15 months respec-
tively. Would the benefit of an ICD in these RCTs have been so
great had trial follow-up been longer?
This question arises within the broader issue of whether
evidence from historic ICD trials remains enduringly robust
in the modern era. Across the key trials of both primary and
secondary prevention therapy (amongst the latter group of
which it should be noted that not all patients had LVSD),
prescription rates of ACE-inhibitors, ARBs, beta-blockers
and MRAs were either sub-optimal by contemporary stan-
dards or not recorded (in which scenario utilisation was likely
low). Moreover, sacubitril-valsartan was not yet available and
few patients would have received CRT, which was still an
investigational device during the enrolment periods of most
of these trials. If the RCTs upon which the guidelines are
based were repeated today, howmight this range of prognostic
therapies, appropriately applied, affect the result? Randomised
data regarding the benefit of catheter ablation for secondary
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prevention of ventricular arrhythmias are lacking; however,
this treatment too would now be available for the control
group if the secondary prevention ICD trials were re-run. An
updated trial of primary prevention ICDs in patients with ICM
will surely be performed at some point. Will anyone be cou-
rageous enough to perform a similar trial of secondary pre-
vention ICDs?
A pressing challenge is to better identify patient subgroups
likely to benefit from an ICD beyond relatively blunt risk
stratifiers such as LVEF, NYHA classification and ischemic
aetiology of heart failure. A vast array of parameters has been
evaluated without overwhelming success, including laborato-
ry indices and biomarkers, electrocardiographic and function-
al variables, novel echocardiographic techniques such as glob-
al longitudinal strain, tissue characterisation by CMR and spe-
cial imaging modalities such as Iodine-123 meta-
iodobenzylguanidine (123I-mIBG). A selection of ongoing re-
search studies is presented in Table 2. These largely focus on
refining patient selection within populations with an existing
indication for a defibrillator, or identifying patients who might
benefit amongst populations without an existing indication
e.g. primary prevention ICDs in patients with LVEF > 35%.
In the former category, the challenge will be to sub-select
patients with the lowest competing risk of non-sudden mor-
tality amongst those with established high risk of SCD. In the
latter category, the competing risk of pump failure death will
certainly be lower than in patients with LVEF ≤ 35%, but will
their risk of arrhythmic SCD be sufficiently high? In a recent
study of 912 unselected ‘sudden’ deaths in the United States,
rigorous application of World Health Organisation diagnostic
criteria for SCD by investigators resulted in the reclassifica-
tion of >40% of deaths as non-sudden. [46] Less than half of
presumed SCDs were adjudicated as being of arrhythmic
aetiology. This suggests that the capacity of an ICD to reduce
sudden deaths amongst populations without an existing indi-
cation for a defibrillator may be lower thanmight otherwise be
assumed.
For completeness, it should also be noted that, although rel-
atively rare, proarrhythmic gene defects (e.g. Lamin A/C) and
other inherited primary arrhythmia syndromes (e.g. the Brugada
and Long or Short QT Syndromes) may occasionally identify
patients at sufficiently high risk of SCD to warrant an ICD.
Similarly, guideline recommendations exist [19, 20] for ICD
use in a range of structural heart diseases (e.g. certain congenital
heart defects and hypertrophic, restrictive, or arrhythmogenic
right ventricular, cardiomyopathies), systemic diseases with car-
diac involvement (e.g. sarcoidosis) and several other special
populations (such as certain patients with a ventricular assist
device or awaiting—or in receipt of—a cardiac transplant).
There is a paucity of robust evidence for such niche indications,
which are themselves beyond the scope of this review.
A final question is the extent to which further advances in
the ICD itself might be important. The development of
transvenous systems, anti-tachycardia pacing, biphasic shock
generators, improved battery technology (limiting the need for
generator replacements), telemetry capability, and most re-
cently the emergence of superior programming configura-
tions, have refined the risk-benefit ratio intrinsic to the devices
themselves (as opposed to that conferred by the characteristics
of the recipient). Amongst patients in the AVID trial who died
suddenly despite an ICD, there was the suggestion that a sig-
nificant proportion of deaths was attributable to the failure of
the defibrillator to terminate a VA [47]. By contrast, in the
modern era ICDs abort ≥ 95% of malignant VAs [48].
Similarly, considering the supposition that treatment with an
ICD might have directly increased non-sudden cardiac mor-
tality in earlier ICD trials, such a trend was not detectable in
DANISH, which thus far is the only primary prevention trial
to have implemented ‘MADIT-RIT programming’, and con-
sequently reported a comparatively low number of inappro-
priate shocks. It is unclear how much benefit can be wrought
from further technical improvements in the functionality of an
ICD, but it seems likely that most of the gains have already
been made. The place of alternative ICD delivery systems—
namely subcutaneous devices and non-implanted, wearable
devices—remains to be fully elucidated and detailed discus-
sion of them is beyond the remit of this review.
Conclusion
Which patients stand to benefit from an ICD? At first glance,
this would appear to be patients with a high risk of arrhythmic
SCD and relatively low risk of other modes of death. This
ostensibly leads to the assumption that ICDs must reduce
mortality for populations in which these characteristics are
observed. However, as suggested in DINAMIT and IRIS, pa-
tients who require defibrillator shocks to abort malignant VAs
may be at higher risk of other modes of death than apparently
similar patients who do not. Therefore, a more robust answer
is: those patients with a sufficiently high risk of arrhythmic
SCD and sufficiently low risk of all other modes of death even
when treated with a defibrillator. The determination of wheth-
er an ICD reduces mortality is thus impossible tomake outside
of a randomised trial. Hazard ratios for ACM in the major
primary and secondary prevention RCTs reflect broad popu-
lations fitting this description. However, scrutiny of the evi-
dence affirms that decisions regarding an ICD should be tai-
lored to individual risk, regardless of whether that person
meets the wider inclusion criteria of a positive trial.
Consideration should be made, for example, of age, aetiology
of heart failure and/or presence of CAD, history of syncope,
NYHA functional class, severity of comorbidity, tolerated
pharmacologic therapy and the presence of—or suitability
for—CRT. To differing degrees, this premise holds true re-
gardless of the indication for a defibrillator. The complexity
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of this situation has been compounded by the revolution in
prognostic therapies for LVSD with or without heart failure
over the past three decades, which means that the absolute
validity of historical trial evidence is open to question. It is
increasingly obvious that new RCTs are necessary, and the
possible variations upon these are extensive [49]. What re-
mains to be seen is how far trial investigators will dare to go
in re-challenging the evidence base.
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